150 related articles for article (PubMed ID: 27726016)
21. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
22. Spatial dose mapping for individualizing radioiodine treatment.
Lassmann M; Hänscheid H
J Nucl Med; 2007 Jan; 48(1):2-4. PubMed ID: 17204691
[No Abstract] [Full Text] [Related]
23. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline].
Dietlein M; Grünwald F; Schmidt M; Schneider P; Verburg FA; Luster M
Nuklearmedizin; 2016 Dec; 55(6):213-220. PubMed ID: 27922153
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
25. Radioactive iodine treatment for differentiated thyroid carcinoma in Japan.
Okamoto T
Surgery; 2010 Mar; 147(3):432-3. PubMed ID: 20176244
[No Abstract] [Full Text] [Related]
26. [Radioiodine treatment of differentiated thyroid carcinomas: residual ablation].
Konrády A
Orv Hetil; 2002 Jun; 143(25):1557; author reply. PubMed ID: 12577410
[No Abstract] [Full Text] [Related]
27. [Guidelines for radio-iodine (131I) therapy in Graves' disease and thyroid cancer].
Mori Y; Kusakabe K; Ikekubo K; Ishikawa N; Nakada K; Kanaya S; Misaki T; Yokoyama K; Kubo A; Higashi T; Itou K; Noguchi Y; Tsuchimochi S; Togawa T;
Kaku Igaku; 2005 Feb; 42(1):17-32. PubMed ID: 15794118
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Follow-Up for Differentiated Thyroid Carcinoma Patients: A Reconsideration.
van der Wardt RA; Persoon AC; Klein Hesselink EN; Links TP
Thyroid; 2017 Mar; 27(3):475-476. PubMed ID: 28049373
[No Abstract] [Full Text] [Related]
29. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.
Roos DE; Smith JG
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):493-5. PubMed ID: 10348276
[TBL] [Abstract][Full Text] [Related]
30. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
[TBL] [Abstract][Full Text] [Related]
32. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.
Moore MD; Postma E; Gray KD; Ullmann TM; Hurley JR; Goldsmith S; Sobel VR; Schulman A; Scognamiglio T; Christos PJ; Hassett E; Luick J; Whitehall D; Zarnegar R; Fahey TJ
World J Surg; 2018 Feb; 42(2):343-349. PubMed ID: 29058064
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategy of papillary microcarcinoma of the thyroid gland: a nuclear medicine perspective.
Riemann B; Schober O
Minerva Endocrinol; 2009 Mar; 34(1):81-7. PubMed ID: 19209130
[TBL] [Abstract][Full Text] [Related]
34. [Indications for adjuvant therapy of thyroid cancer with radioiodine therapy].
Jarzab B
Wiad Lek; 2001; 54 Suppl 1():254-65. PubMed ID: 12182034
[TBL] [Abstract][Full Text] [Related]
35. ¹³¹I sodium-iodide versus ⁵⁶Fe surgical steel. Which is better for lateral lymph node metastases in differentiated thyroid cancer patients?
Verburg F; Weber T; Luster M
Nuklearmedizin; 2013; 52(4):113-4. PubMed ID: 23928980
[No Abstract] [Full Text] [Related]
36. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.
Zanotti-Fregonara P; Grassetto G; Hindié E; Rubello D
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):169-71. PubMed ID: 18850097
[No Abstract] [Full Text] [Related]
37. Postsurgical management of differentiated thyroid carcinoma.
Mazzaferri EL; Robyn J
Otolaryngol Clin North Am; 1996 Aug; 29(4):637-62. PubMed ID: 8844735
[TBL] [Abstract][Full Text] [Related]
38. An interesting contamination artifact appearing in I-(131) whole-body imaging after ablative therapy.
Ozcan Kara P; Sari O; Gedik GK; Kocak I; Kaya B
Rev Esp Med Nucl; 2011; 30(1):36-7. PubMed ID: 21211869
[No Abstract] [Full Text] [Related]
39. [Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer].
Dietlein M; Dressler J; Farahati J; Leisner B; Moser E; Reiners C; Schicha H; Schober O
Nuklearmedizin; 1999; 38(6A):221-2. PubMed ID: 10510812
[No Abstract] [Full Text] [Related]
40. [Determining the activities of 131I with dose-rate constraint method for the treatment of differentiated thyroid carcinoma with diffuse pulmonary metastases].
Liu B; Zeng Y; Wang JT; Zhao Z; Mu D; Kuang AR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May; 41(3):513-7. PubMed ID: 20629335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
